Decreased insulin resistance in diabetic patients by influencing Sirtuin1 and Fetuin-A following supplementation with ellagic acid: a randomized controlled trial

Table 1 The comparison of baseline characteristics of the participants

Variable	Mean ± SD Placebo (n = 21)	Mean ± SD Ellagic acid (n = 21)	P1
Age (years)	44.04 ± 6.88	47 ± 5.06	0.701
Height(cm)	163.71 ± 9.12	162.43 ± 10.59	0.814
Weight (kg)
Before	68.95 ± 9.02	67.23 ± 10.24	0.621
After	68.49 ± 9.21	66.98 ± 10.31	0.59
P2	0.78	0.619
Body mass index (K g/m²)
Before	25.61 ± 0.86	25.32 ± 1.07	0.562
After	25.43 ± 0.9	25.22 ± 1.09	0.604
P2	0.719	0.807
Physical activity
Before	37.27 ± 2.78	36.15 ± 2.99	0.132
After	37.5 ± 3.31	36.43 ± 2.89	0.108
P2	0.429	0.49
Metformin dose	1643.17 ± 377.88	1610.4 ± 362.07	0.88

Data are expressed as means ± SD
P1: Comparison of the mean of baseline characteristics between the two groups of Ellagic acid and placebo (Independent samples t-test)
P2: Comparison of mean of baseline characteristics in each group at baseline and end of study (Paired samples t-test)

ISSN: 1758-5996